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Abstract
Background: Many older patients don’t receive appropriate oncological treatment. Our aim was to analyse whether
there are age differences in the use of adjuvant chemotherapy and preoperative radiotherapy in patients with
colorectal cancer.
Methods: A prospective cohort study was conducted in 22 hospitals including 1157 patients with stage III
colon or stage II/III rectal cancer who underwent surgery. Primary outcomes were the use of adjuvant
chemotherapy for stage III colon cancer and preoperative radiotherapy for stage II/III rectal cancer. Generalised
estimating equations were used to adjust for education, living arrangements, area deprivation, comorbidity
and clinical tumour characteristics.
Results: In colon cancer 92% of patients aged under 65 years, 77% of those aged 65 to 80 years and 27% of
those aged over 80 years received adjuvant chemotherapy (χ2trends < 0.001). In rectal cancer preoperative radiotherapy
was used in 68% of patients aged under 65 years, 60% of those aged 65 to 80 years, and 42% of those aged over 80 years
(χ2trends < 0.001). Adjusting by comorbidity level, tumour characteristics and socioeconomic level, the odds ratio of use of
chemotherapy compared with those under age 65, was 0.3 (0.1–0.6) and 0.04 (0.02–0.09) for those aged 65 to 80
and those aged over 80, respectively; similarly, the odds ratio of use of preoperative radiotherapy was 0.9 (0.6–1.4)
and 0.5 (0.3–0.8) compared with those under 65 years of age.
Conclusions: The probability of older patients with colorectal cancer receiving adjuvant chemotherapy and preoperative
radiotherapy is lower than that of younger patients; many of them are not receiving the treatments recommended by
clinical practice guidelines. Differences in comorbidity, tumour characteristics, curative resection, and socioeconomic
factors do not explain this lower probability of treatment. Research is needed to identify the role of physical and cognitive
functional status, doctors’ attitudes, and preferences of patients and their relatives, in the use of adjuvant therapies.
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Background
Evidence suggests that older patients can benefit from
aggressive therapies as much as younger individuals can,
improving their overall and disease-free survival [1].
Nevertheless, a high percentage of older patients do not
receive standard cancer treatments [2–5]. A European
study found that 69% of patients under 65 years old and
only 16% of those over this age received adjuvant chemo-
therapy for stage III colon cancer [4]. Several authors have
shown that these differences remain after adjusting for
comorbidity [2, 6]. Age has also been associated with the
frequency of use of radiotherapy [7–9]. In Sweden, pre-
operative radiotherapy for rectal cancer was given to 64%
of patients under 65 years old, to 50% of 65 to 79 years old
and to 15% of those 80 years of age or older [7]. In
Canada, Eldin et al. observed that after adjusting for co-
morbidity and stage, age was the most important factor in
determining the use of radiotherapy [9]. Most of the
revised studies have reported results adjusting for comor-
bidity and stage, but studies are scarce that in addition
have adjusted for the patient’s social position and living
arrangements. None of the multicentre studies has taken
into account the inter-hospital variability both in clinical
practice and in hospital area’s material deprivation.
A greater toxicity of chemotherapy and radiotherapy in
older patients with colorectal cancer might explain a lower
adherence to clinical practice guidelines. Further, the ex-
clusion of older patients from clinical trials means that
there is limited scientific evidence concerning the efficacy
and toxicity associated with treatments in this population.
This has led to a lack of evidence-based clinical guidelines
[3]. For tumours at some anatomical sites, radiation ther-
apy has been found to be more toxic in patients of ad-
vanced ages, suggesting a need for closer monitoring [1].
Nevertheless, the majority of clinical trials including older
patients with colorectal cancer have reported toxicity pro-
files similar to those observed in younger patients [10, 11].
In addition to these clinical factors, there are social factors
that may place older patients at a disadvantage with re-
spect to receiving treatments, such as having a lower so-
cioeconomic level [12–14] and a lower level of education
[15], as well as more frequently living alone [16].
The aims of this paper were a) to identify whether there
are differences between age groups in the use of chemo-
therapy for stage III colon cancer and preoperative radio-
therapy for stage II and III rectal cancer; and b) to assess
whether these differences remain after adjusting for co-
morbidity, tumour characteristics, curative resection
and social factors such as economic deprivation or liv-
ing arrangements.
Methods
Data were obtained by conducting a prospective multi-
centre cohort study in 22 hospitals in five autonomous
regions in Spain. We included patients with primary in-
vasive colon or rectal cancer who underwent pro-
grammed or urgent surgery between April 2010 and
December 2012. A detailed protocol was published by
Quintana et al. [17]. Among the 3315 patients who met
the inclusion criteria, 41 were excluded from the study
due to poor physical or cognitive status, and we failed to
contact another 288. In addition, 237 (7.2%) declined to
participate in the study (Fig. 1).
Outcomes and covariates
The primary outcomes analysed were the use of adjuvant
chemotherapy in stage III colon cancer and preoperative
radiotherapy in stage II and III rectal cancer. Age was
assessed at the time of diagnoses and arbitrarily catego-
rized into three groups: younger (under 65 years of age),
older (65 to 80 years) and oldest (over 80 years) patients.
We assessed prognostic factors, which according to
the scientific literature, might be unevenly distributed
between age groups: a) Social and economic variables:
socioeconomic level, considering level of education and
area of residence deprivation, which was calculated fol-
lowing the methodology of Esnaola et al. [18], for each
census tract based on five 2001 census indicators related
to occupation and educational attainment; living ar-
rangements (alone or with others);
b) health behaviours: alcohol intake (greater than 80 g/day
or not) and smoking habits (current smoker, ex-smoker,
never smoker);
c) cancer family history and whether the diagnosis had
been made through a screening programme or not;
d) health status: comorbidities, measured using the
Charlson comorbidity index (CCI) [19], stratifying pa-
tients into three groups (0, 1, and 2 or more), and the
American Society of Anesthesiologists (ASA) class [20],
a proxy for the severity of patients’ comorbidities;
e) tumour characteristics: site (proximal colon, distal
colon, rectosigmoid junction or rectum), histological
findings (adenocarcinoma, mucinous adenocarcinoma,
signet ring cell carcinoma, others), degree of differenti-
ation (low, corresponding to tumours that are well or
moderately well differentiated, or high, corresponding to
poorly differentiated and undifferentiated tumours); h)
tumour stage (according to the 7th edition of the TNM
classification of the Union for International Cancer Con-
trol), assigning patients who underwent neoadjuvant treat-
ment a clinical stage and those who underwent surgery as
the first treatment a pathological stage, for statistical
analysis;
f ) surgery: profile of the surgeon (fully dedicated to
coloproctology or not); type of surgery (elective/emer-
gency); curative resection (no residual tumour (R0) or
microscopic/macroscopic remnant of the tumour (R1/
R2)); and finally whether a cancer committee was
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involved in the patient’s management, as a process
indicator.
Statistical analysis
First, potential prognostic factors were compared among
the three age groups using Pearson chi-square test (χ2)
and chi square test for trends (χ2trends). Then, the univar-
iate association of each factor with the use of adjuvant
chemotherapy and preoperative radiotherapy was inves-
tigated using Pearson chi square test for the categorical
non ordinal variables and chi square test for trends for
the ordinal variables. Multivariable analyses were per-
formed with Generalised Estimating Equations, cluster-
ing by hospital, to assess the association between age
and the use of chemotherapy and preoperative radio-
therapy, adjusting for sociodemographic and clinical
factors. This approach enabled us to construct multivariate
models that take into account the correlation between indi-
viduals from the same hospital. An unstructured variance-
covariance matrix was used. Potential confounders with
p < 0.2 in the univariate analysis were entered simultan-
eously in the multivariable model using dummy variables.
Missing data were imputed using the multiple imputation
method available in SPSS which uses by default 5 iterations.
The imputed variables were: level of education, deprivation
index, screening, ASA class and alcohol intake. The vari-
ables used for the imputation were as follows: age, level of
education, deprivation index, autonomous region, CCI,
ASA class, alcohol intake and surgeon profile. The calcu-
lated measure of association was the odds ratio with the
corresponding 95% confidence interval. Two-tailed tests
were used, considering p values < 0.05 to be statistically
significant. The analysis was performed using IBM
SPSS, Statistics for Windows, v23, and Stata v14.
Results
A total of 2749 patients were finally included in the
study, among whom 654 had stage III colon cancer and
503 stage II or III rectal cancer (Fig. 1). This research re-
port refers to these 1157 patients.
Patients included were significantly older than those
who were excluded or not contactable (p, χ2 < 0.005),
but differences with those who declined to participate
were not statistically significant.
Of the included patients, 38.8% were under 65 years,
47.2% were between 65 and 80 years, and 13.9% were
over 80 years of age. Approximately two thirds (65.2%)
were men. Overall, 13% had not completed any formal
education, and only 12% had university qualifications
(short- or long-cycle degrees). Most participants (86%)
lived with a relative.
Tables 1 and 2 indicate the observed differences be-
tween age groups, for colon and rectum respectively.
Older patients were more likely to have a low education
level (p, χ2trends < 0.0005) and to live alone (p, χ
2 <
0.0005). No significant differences were found in
deprivation of the area of residence (p = 0.9). Younger
patients were more likely to report a family history of
cancer (p, χ2 < 0.05). The proportion of patients who
have never smoked increases with age (p, χ2 < 0.05) and
comorbidity increases with age (p, χ2trends < 0.0005). In
colon cancer there were no age significant differences in
tumour sites, histological classification, degree of differ-
entiation or, in rectal cancer, in stage at diagnosis. Fi-
nally, we did not find differences in curative resections
(R0) by age.
Among the main differences in colon and rectal can-
cer, we highlight the following: younger patients were
more likely to have undergone screening (p, χ2 < 0.0005)
in colon cancer but there were no significant differences
Fig. 1 Flowchart of patients through the study and reasons for non-inclusion
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Table 1 Distribution of social, health and clinical patient’s variables by age groups in stage III colon cancer (n = 654)
N < 65 years
N = 246
n (%)
65–80 years
N = 311
n (%)
> 80 years
N = 97
n (%)
P valuea
Sociodemographic variables
Sex 654
Male 151 (61.4) 205 (65.9) 60 (61.9) 0.50
Female 95 (38.6) 106 (34.1) 37 (38.1) 0.65
Deprivation index 624
Quartile 1 least deprived 49 (21.2) 67 (22.3) 17 (18.5) 0.67
Quartile 2 64 (27.7) 101 (33.6) 31 (33.7) 0.78
Quartile 3 67 (29.0) 72 (23.9) 22 (23.9)
Quartile 4 most deprived 51 (22.1) 61 (20.3) 22 (23.9)
Level of education 534
Illiterate or with no formal education 10 (4.8) 46 (18.2) 15 (20.5) < 0.0005
Primary 123 (59.1) 162 (64.0) 50 (68.5) < 0.0005
Secondary 35 (16.8) 24 (9.5) 3 (4.1)
University 40 (19.2) 21 (8.3) 5 (6.8)
Living arrangements 522
Living alone 23 (11.5) 42 (17.0) 14 (18.7) 0.18
Living with others 177 (88.5) 205 (83.0) 61 (81.3) 0.08
Family history of cancer 584
No 118 (52.2) 175 (63.9) 68 (81.0) < 0.0005
Yes 108 (47.8) 99 (36.1) 16 (19.0) < 0.0005
Screening 622
No 174 (74.0) 250 (84.7) 86 (93.5) < 0.0005
Yes 61 (26.0) 45 (15.3) 6 (6.5) < 0.0005
Health behaviours and comorbidities
Smoking habits 648
Never smoker 112 (45.5) 154 (50.0) 50 (53.2) 0.01
Current smoker 42 (17.1) 31 (10.1) 4 (4.3) 0.79
Ex-smoker 92 (37.4) 123 (39.9) 40 (42.6)
Alcohol 612
No 188 (83.9) 257 (86.2) 84 (93.3) 0.09
Yes 36 (16.1) 41 (13.8) 6 (6.7) 0.04
ASA class 633
I-II 175 (73.2) 157 (52.2) 30 (32.3) < 0.0005
III 60 (25.1) 127 (42.2) 52 (55.9) < 0.0005
IV 4 (1.7) 17 (5.6) 11 (11.8)
Charlson Index 654
0 163 (66.3) 158 (50.8) 40 (41.2) < 0.0005
1 49 (19.9) 80 (25.7) 26 (26.8) < 0.0005
≥ 2 34 (13.8) 73 (23.5) 31 (32.0)
Tumour characteristics
Site 654
Rectosigmoid junction 40 (16.3) 45 (14.5) 11 (11.3) 0.72
Distal colon 108 (43.9) 140 (45.0) 41 (42.3) 0.21
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in rectal cancer; among those with colon cancer, patients
over 80 years of age were more likely to have had emer-
gency surgery (p, χ2 = 0.04) compared with those under
age 80; with increasing age, the number of surgical inter-
ventions done by surgeons specialized in coloproctology
decreased (p, χ2trends = 0.04) and the proportion of cases
reviewed by an interdisciplinary tumor committee de-
creased (p, χ2trends = 0.004). These differences were not
observed among those with rectal cancer.
Table S1 reports the frequencies of imputed variables
before and after imputation. The distribution of the im-
puted values can be seen to be homogenous (Additional
file 1: Table S1).
Adjuvant chemotherapy for patients with colon cancer
Of the 654 patients with stage III colon or rectosigmoid
cancer identified, 75% received chemotherapy after sur-
gical resection. Table 3A summarises the univariate asso-
ciation of patient characteristics with chemotherapy. The
use of this therapy decreased significantly with age, from
91.9% in the youngest age group to 76.7% in the older
group to only 26.8% in the oldest patients (p, χ2trends <
0.0005). No significant difference in use of adjuvant
chemotherapy was observed by sex. A higher level of
comorbidity was also associated with less use of chemo-
therapy, with a rate of 82% in patients with no comor-
bidities falling to just 58.7% in those with a CCI of 2 or
more. Nevertheless, we should note that even among
patients with no comorbidities, older age was also asso-
ciated with less use of chemotherapy; the rates were 94,
82 and 33% for those under 65, between 65 and 80, and
over 80 years of age, respectively (p, χ2trends < 0.0005)
(Fig. 2). Table 3B shows the multivariable results. There
was a significant negative association between age and the
use of chemotherapy after simultaneously adjusting for
comorbidity, tumour characteristics (such as the site and
degree of differentiation) and level of education. Compared
to younger patients, the adjusted OR was 0.3 (95% CI: 0.1–
0.6) for the older and 0.04 (95% CI: 0.02–0.09) for the
oldest age groups. We found no significant association
between chemotherapy use and either participation of the
cancer committee in the management of the patient or the
surgeon’s specialisation. The outcome of the surgery did
not have a significant effect on the chemotherapy use.
Table 1 Distribution of social, health and clinical patient’s variables by age groups in stage III colon cancer (n = 654) (Continued)
N < 65 years
N = 246
n (%)
65–80 years
N = 311
n (%)
> 80 years
N = 97
n (%)
P valuea
Proximal colon 98 (39.8) 126 (40.5) 45 (46.4)
Histological classification 643
Adenocarcinoma 219 (91.3) 274 (89.3) 87 (90.6) 0.18
Mucinous adenocarcinoma 16 (6.7) 27 (8.8) 9 (9.4) 0.69
Signet-ring cell carcinoma 2 (0.8) 6 (2.0) 0 (0.0)
Other types of carcinoma 3 (1.3) 0 (0.0) 0 (0.0)
Degree of differentiation 573
Low grade 165 (79.3) 226 (81.9) 79 (88.8) 0.15
High grade 43 (20.7) 50 (18.1) 10 (11.2) 0.07
Intervention
Main intervention 654
Elective 232 (94.3) 300 (96.5) 87 (89.7) 0.03
Emergency 14 (5.7) 11 (3.5) 10 (10.3) 0.32
Curative resection 618
R0 218 (92.4) 261 (90.0) 84 (91.3) 0.63
R1 / R2 18 (7.6) 29 (10.0) 8 (8.7) 0.56
Surgeon’s profile 615
General 61 (27.0) 96 (32.5) 36 (38.3) 0.12
Coloproctologist 165 (73.0) 199 (67.5) 58 (61.7) 0.04
Cancer committee 617
No 77 (32.9) 127 (43.6) 44 (47.8) 0.01
Yes 157 (67.1) 164 (56.4) 48 (52.2) 0.004
aPearson Chi-square test to generate upper P value and chi-square test for trends to generate lower P value
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Table 2 Distribution of social, health and clinical patient’s variables by age groups in stage II, III rectal cancer (n = 503)a
N < 65 years
N = 203
n (%)
65–80 years
N = 235
n (%)
> 80 years
N = 64
n (%)
P valueb
Sociodemographic variables
Sex 502
Male 128 (63.1) 169 (71.9) 41 (64.1) 0.12
Female 75 (36.9) 66 (28.1) 23 (35.9) 0.35
Deprivation index 476
Quartile 1 least deprived 28 (14.7) 41 (18.6) 12 (18.8) 0.66
Quartile 2 68 (35.6) 72 (32.6) 16 (25.0) 0.80
Quartile 3 57 (29.8) 71 (32.1) 24 (37.5)
Quartile 4 most deprived 38 (19.9) 37 (16.7) 12 (18.8)
Level of education 408
Illiterate or with no formal education 9 (5.3) 30 (15.9) 11 (22.4) < 0.0005
Primary 100 (58.8) 137 (72.5) 33 (67.3) < 0.0005
Secondary 34 (20.0) 8 (4.2) 1 (2.0)
University 27 (15.9) 14 (7.4) 4 (8.2)
Living arrangements 403
Living alone 11 (6.7) 30 (15.8) 9 (18.8) 0.01
Living with others 154 (93.3) 160 (84.2) 39 (81.3) 0.005
Family history of cancer 464
No 97 (51.9) 126 (58.3) 42 (68.9) 0.06
Yes 90 (48.1) 90 (41.7) 19 (31.1) 0.02
Screening 478
No 167 (87.0) 199 (88.8) 58 (93.5) 0.36
Yes 25 (13.0) 25 (11.2) 4 (6.5) 0.18
Health behaviours and comorbidities
Smoking habits 498
Never smoker 82 (40.4) 104 (44.8) 37 (58.7) 0.001
Current smoker 49 (24.1) 30 (12.9) 3 (4.8) 0.37
Ex-smoker 72 (35.5) 98 (42.2) 23 (36.5)
Alcohol 483
No 175 (89.3) 198 (87.2) 56 (93.3) 0.39
Yes 21 (10.7) 29 (12.8) 4 (6.7) 0.70
ASA class 490
I-II 144 (73.1) 118 (51.5) 31 (48.4) < 0.0005
III 51 (25.9) 101 (44.1) 31 (48.4) < 0.0005
IV 2 (1.0) 10 (4.4) 2 (3.1)
Charlson Index 502
0 134 (66.0) 118 (50.2) 25 (39.1) < 0.0005
1 43 (21.2) 60 (25.5) 18 (28.1) < 0.0005
≥ 2 26 (12.8) 57 (24.3) 21 (32.8)
Tumour characteristics
Histological classification 467
Adenocarcinoma 181 (96.8) 201 (92.6) 58 (92.1) 0.05
Mucinous adenocarcinoma 5 (2.7) 16 (7.4) 4 (6.3) 0.05
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The most frequent chemotherapy schemes were
CAPOX (capecitabine, oxaliplatin) in 49.4% of patients,
FOLFOX (5- Fluorouracil, oxaliplatin) in 26.9% and
capecitabine in monotherapy in 20% of the cases. Oxali-
platin-based adjuvant chemotherapy administration var-
ied with age as follows: 83.4% in the younger group,
64.2% in the older and 29% in the oldest (p, χ2trends <
0.0005). The administration of capecitabine in mono-
therapy was 11.7, 24.6 and 57.9%, respectively, (p,
χ2trends < 0.0005).
Preoperative radiotherapy for patients with rectal cancer
Of the 503 patients with stage II and III rectal cancer,
61% received radiotherapy before surgical intervention.
Table 4A shows the univariate association of patient
characteristics with preoperative radiotherapy. It was ob-
served that its use decreased significantly with age, from
68% in the youngest age group to 60.4% in the older to
42.2% in the oldest patients (p, χ2trends < 0.0005). No sig-
nificant association was observed between preoperative
radiotherapy and sex or with socioeconomic characteris-
tics or living arrangements. We also found significant
differences in patients with no comorbidities, with rates
of use of 70, 64 and 40% in the three age groups, respect-
ively (p, χ2trends = 0.009) (Fig. 3). After simultaneously
adjusting for family history of cancer, comorbidities and
their severity, and tumour stage (Table 4B), age remained
the main predictor. Compared to younger patients, the ad-
justed OR for the oldest patients was 0.5 (95% CI: 0.3–
0.8), while the odds in the group of patients aged 65 to 80
years was not significantly lower with respect to the youn-
gest group. We found no association of CCI or ASA with
the use of radiotherapy, but family history was associated
with a higher odds of use (OR = 1.5, 95% CI: 1.0–2.2), as
was the tumour stage (OR = 2.8, 95% CI: 1.5–4.9).
Discussion
Chemotherapy
In our cohort of patients treated between 2010 and
2012, we found that 70% of all stage III patients with
colon cancer received chemotherapy; however, its use
dramatically decreased with age, with a percentage of
92% in under-65-year-olds but only 27% among over-80-
year-olds. Data from Europe and Australia, where there
are health systems with quasi-universal coverage as in
Spain, indicate that no more than 20–25% of patients
Table 2 Distribution of social, health and clinical patient’s variables by age groups in stage II, III rectal cancer (n = 503)a (Continued)
N < 65 years
N = 203
n (%)
65–80 years
N = 235
n (%)
> 80 years
N = 64
n (%)
P valueb
Signet-ring cell carcinoma 1 (0.5) 0 (0.0) 0 (0.0)
Other types of carcinoma 0 (0.0) 0 (0.0) 1 (1.6)
Degree of differentiation 389
Low grade 137 (86.7) 153 (86.0) 48 (90.6) 0.68
High grade 21 (13.3) 25 (14.0) 5 (9.4) 0.62
Stage at diagnosis (pTNM or cTNM) 502
II 61 (30.0) 76 (32.3) 27 (42.2) 0.19
III 142 (70.0) 159 (67.7) 37 (57.8) 0.11
Intervention
Main intervention 502
Elective 200 (98.5) 234 (99.6) 64 (100.0) 0.35
Emergency 3 (1.5) 1 (0.4) 0 (0.0) 0.16
Curative resection 476
R0 162 (84.4) 193 (85.4) 52 (89.7) 0.60
R1/R2 30 (15.6) 33 (14.6) 6 (10.3) 0.37
Surgeon’s profile 476
General 59 (30.3) 71 (32.3) 18 (29.5) 0.87
Coloproctologist 136 (69.7) 149 (67.7) 43 (70.5) 0.92
Cancer committee 418
No 52 (27.2) 74 (33.2) 19 (29.7) 0.42
Yes 139 (72.8) 149 (66.8) 45 (70.3) 0.42
aAge was missing in a case
bPearson Chi-square test to generate upper P value and chi-square test for trends to generate lower P value
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Table 3 Crude and adjusted analysis of the association between age and adjuvant chemotherapy in stage III colon cancer
Adjuvant chemotherapy for stage III colon cancer
3A. Univariate analysis 3B. Multivariate analysis
n (%) P value Odds Ratio (95% CI) P value
Age, years
< 65 226 (91.9) < 0.0005b 1
65–80 239 (76.8) 0.3 (0.1–0.6) 0.001
> 80 26 (26.8) 0.04 (0.02–0.09) < 0.0005
Sex
Male 309 (74.3) 0.57a
Female 182 (76.5)
Deprivation index
Quartile 1 106 (79.7) 0.29b
Quartile 2 142 (72.4)
Quartile 3 121 (75.2)
Quartile 4 97 (72.4)
Level of education
No formal 47 (66.2) < 0.0005b 1
Primary 253 (75.5) 1.2 (0.7–2.2) 0.46
Secondary 53 (85.5) 1.6 (0.4–5.5) 0.46
University 59 (89.4) 1.6 (0.5–5.7) 0.45
Living arrangement
Living alone 56 (70.9) 0.2a
Living with others 345 (77.9)
Family history of cancer
No 257 (71.2) < 0.0005a 1
Yes 194 (87.0) 1.9 (0.7–5.0) 0.21
Screening
No 368 (72.2) 0.001a 1
Yes 97 (86.6) 1.0 (0.4–2.2) 0.99
Smoking habits
Never smoker 241 (76.3) 0.516a
Current smoker 61 (79.2)
Ex-smoker 187 (73.3)
Alcohol
No 392 (74.1) 0.42a
Yes 63 (75.9)
Charlson index
0 296 (82.0) < 0.0005b 1
1 114 (73.5) 0.8 (0.5–1.4) 0.43
≥ 2 81 (58.7) 0.6 (0.3–1.2) 0.17
ASA class
I-II 309 (85.4) < 0.0005b 1
III 155 (64.9) 0.6 (0.3–1.1) 0.10
IV 10 (31.3) 0.1 (0.03–0.3) < 0.0005
Site
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over 75 years old received adjuvant chemotherapy in
2000. In the USA, these percentages reach 40 to 50%
[21]. In Spain, on the basis of population data, a study
reported that the percentages of chemotherapy use fall
from 61% in under-75-year-olds to 27% in patients
75 years of age or older [22].
In our study, a quarter of patients between 65 and
80 years old did not receive any chemotherapy. In
some patients, this is attributable to a higher level of
comorbidity, but we observed that the pattern remains
even in patients with no comorbidities. Moreover, vari-
ables such as high alcohol intake, tumour characteristics
(site and histological findings), and even curative resection
had less influence than age on the decision of whether to
treat. This is consistent with previous scientific reviews
that have demonstrated a lower use of chemotherapy
among the older even after adjusting for comorbidity and
other relevant clinical variables [2, 21].
A low level of education, area of residence deprivation
and marital status have been reported to be associated
with lower probability of treatment [15, 23, 24]. In our
study, we have observed that the magnitude of the
Table 3 Crude and adjusted analysis of the association between age and adjuvant chemotherapy in stage III colon cancer
(Continued)
Adjuvant chemotherapy for stage III colon cancer
3A. Univariate analysis 3B. Multivariate analysis
n (%) P value Odds Ratio (95% CI) P value
Rectosigmoid junction 78 (81.3) 0.19a 1
Distal colon 219 (75.8) 0.5 (0.2–1.4) 0.18
Proximal colon 194 (72.1) 0.5 (0.2–1.6) 0.25
Degree of differentiation
Low grade 354 (75.3) 0.12a 1
High grade 85 (82.5) 1.2 (0.4–3.4) 0.70
Histological classification
Adenocarcinoma 439 (75.7) 0.29a
Mucinous Adenocarcinoma 38 (73.1)
Signet-ring cell carcinoma 8 (100.0)
Other carcinomas 3 (100.0)
Cancer committee
No 180 (72.6) 0.30a
Yes 282 (76.4)
Surgeon’s profile
General 134 (69.4) 0.07a 1
Coloproctologist 323 (76.5) 1.3 (0.6–3.1) 0.50
Curative resection
R0 428 (76.0) 0.62a
R1/R2 40 (72.7)
aPearson Chi-square test
bChi-square test for trends
Fig. 2 Percentage of patients with stage III colon cancer who
received chemotherapy by age and number of comorbidities.
Legend: Age (years) < 65, 65–80, > 80
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Table 4 Crude and adjusted analysis of the association between age and preoperative radiotherapy in stage II and III rectal cancer
patients
Preoperative radiotherapy in stage II and III rectal cancer
4A. Univariate analysis 4B. Multivariate analysis
n (%) P value Odds Ratio (95% CI) P value
Age, years
< 65 138 (68.0) < 0.0005b 1
65–80 142 (60.4) 0.9 (0.6–1.4) 0.74
> 80 27 (42.2) 0.5 (0.3–0.8) 0.004
Sex
Male 205 (60.7) 0.85a
Female 102 (61.8)
Deprivation index
Quartile 1 50 (61.7) 0.31b
Quartile 2 86 (54.8)
Quartile 3 94 (61.8)
Quartile 4 57 (65.5)
Level of education
No formal 31 (62.0) 0.78b
Primary 164 (60.5)
Secondary 28 (65.1)
University 25 (55.6)
Living arrangements
Living alone 30 (60.0) 0.88a
Living with others 217 (61.3)
Family history of cancer
No 147 (55.3) 0.005a 1
Yes 136 (68.3) 1.5 (1.0–2.1) 0.05
Screening
No 262 (61.6) 0.30a
Yes 29 (53.7)
Smoking habits
Never smoker 136 (60.7) 0.31a
Current smoker 56 (68.3)
Ex-smoker 113 (58.5)
Alcohol
No 264 (61.4) 0.77a
Yes 32 (59.3)
Charlson index
0 179 (64.6) 0.03b 1
1 74 (60.7) 0.9 (0.6–1.4) 0.77
≥ 2 54 (51.9) 0.9 (0.5–1.7) 0.88
ASA class
I-II 187 (63.8) 0.12b 1
III 106 (57.6) 0.9 (0.6–1.2) 0.39
IV 7 (50.0) 0.8 (0.3–2.4) 0.68
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association between age and chemotherapy does not
change when we adjust for level of education, which
means that the lower level of education in older patients
does not help to explain the differences observed by age
group. The deprivation index and living arrangement
were also not found to be significantly associated with
the use of chemotherapy.
In agreement with previous authors, we observed
that those older than 65 were less likely to be treated
with chemotherapy in spite of its survival advantage
[25, 26]. Furthermore, the very old patients who received
chemotherapy were more likely to be treated with capecit-
abine in monotherapy. Further research needs to be done
in the oldest age groups, who have been excluded from
most clinical trials and for whom little knowledge on
treatment efficacy and safety is available [27].
Preoperative radiotherapy
The percentages of use of preoperative radiotherapy
among patients under 65, between 65 and 80 and over
80 years of age were 68, 60 and 42%, respectively. The
decrease with increasing age remained significant after
adjusting for comorbidities and the other covariates.
Compared to patients under 65 years of age, the adjusted
ORs for patients between 65 and 80 and those over 80
years of age were 0.9 and 0.5, respectively.
Previously available evidence, derived from population-
level data, indicated less use of radiotherapy among older
patients. In Spain, 24% of under-75-year-olds and 11% of
patients 75 years of age or older with colorectal cancer
have received radiotherapy [22, 28]. In Sweden, the use of
preoperative radiotherapy falls from 64% in under-65-
year-olds to 15% in over-80-year-olds [7]. According to a
review by Faivre [21], the rates of pre- and post-operative
radiotherapy ranged from 20 to 50% in different registries
in Europe and the USA.
In our study, comorbidity, area of residence deprivation,
education and living arrangements did not predict the deci-
sion to treat preoperatively with radiotherapy. We did not
find studies that analysed the influence of comorbidities.
Table 4 Crude and adjusted analysis of the association between age and preoperative radiotherapy in stage II and III rectal cancer
patients (Continued)
Preoperative radiotherapy in stage II and III rectal cancer
4A. Univariate analysis 4B. Multivariate analysis
n (%) P value Odds Ratio (95% CI) P value
Degree of differentiation
Low grade 201 (59.5) 0.76a
High grade 29 (56.9)
Histological classification
Adenocarcinoma 268 (60.8) 0.29a
Mucinous adenocarcinoma 13 (52.0)
Stage
II 75 (45.7) < 0.0005a 1
III 232 (68.4) 2.8 (1.5–4.9) 0.001
Cancer committee
No 84 (57.9) 0.48a
Yes 205 (61.6)
Surgeon’s profile
General 91 (61.1) 1.0a
Coloproctologist 201 (61.3)
aPearson Chi-square test
bChi-square test for trends
Fig. 3 Percentage of patients with stage II and III rectal cancer who
received preoperative radiotherapy by age and number of
comorbidities. Legends: Age (years) < 65, 65–80, > 80
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Previous studies have reported living arrangements and
marital status to be significant predictors of the use of
radiotherapy [7, 15, 29]. We should note that in our study,
the percentage of older patients who lived alone was very
low (14%). In other countries, the figures reach 35% in
people above 65 years old and 50% in those above 80 years
of age. This reflects the level of family support, especially
from offspring, for widows/widowers in Spain. In Sweden, a
study reported an association with income but not with
level of education [7].
Another potentially relevant factor is the distance from
the tumour to the anal verge, but there is evidence that
this factor is not associated with age [8]. We did not
study this issue, but some authors have found a strong
association between age and the use of radiotherapy re-
gardless of tumour sub-site location [7].
Limitations
This study has some limitations that should be recog-
nised. We were not able to contact nearly 9% of eligible
patients, and we found that these patients were older
than the participants; hence, the older patients included
may be a biased sample of the older population. If the
clinical status of participants was better than that of
those excluded, we could be underestimating the real
effect of age on the use of cancer treatments. Another
selection bias could be associated with the type of
centres included in the study, given that most of them
were referral hospitals with specialised units.
Regarding comorbidity, it has been suggested that the
CCI may not capture comorbidities well, as it does not
measure the severity of comorbid conditions [30]. To
compensate for this limitation, at least partially, we in-
cluded ASA class as a proxy for disease severity.
Apart from comorbidity, another factor that could justify
a lower use of treatment in older people is a supposedly
greater toxicity. There is some evidence suggesting a lack of
association between age and toxicity [31] or even a lower
incidence of adverse effects in people above 75 years old
[32, 33], attributable to dose reduction and the use of less
aggressive treatment regimens in this age group. A recent
Danish study found that over-70-year-olds with colorectal
cancer were treated with single-agent therapy and at a
lower initial dosage and that this chemotherapy dose reduc-
tion did not have an impact on disease-free survival or can-
cer-specific mortality; these outcomes were only different in
the older patients who received less than half of the full
number of cycles (given to other patients) [11]. Neverthe-
less, other authors have described a higher level of toxicity
with age [2, 34]. In the present study, we did not assess ad-
verse events.
A weakness in determining the causes of the low ad-
herence to clinical practice guidelines for older patients
is the lack of information concerning the functional
status of patients, which might explain treatment decisions.
An alteration in the instrumental activities of daily living
has been significantly associated with chemotherapy-related
toxicity [35]. Further, poor nutritional status has been de-
scribed as a predictor of a lower tolerance to chemotherapy,
and factors such as malnutrition and frailty have been asso-
ciated with higher mortality in patients with colorectal can-
cer undergoing palliative chemotherapy [36]. It would be of
interest to know whether the 41 patients excluded because
of functional limitations received chemo/radio-therapy but
poor functional or cognitive status was used as exclusion
criterion in the main study. In the case of radiotherapy, an-
other factor that might hinder treatment is difficulty of ac-
cess to treatment centres [37], although we think that this
factor would not have a great impact in our setting, given
that when the distance to the hospital is large, public ser-
vices provide transport to patients who need it.
In our study, we did not take into account variables
such as the opinions of doctors and preferences of pa-
tients and their relatives. According to some authors,
the opinions and attitudes of doctors may explain the
low prescription of adjuvant chemotherapy. In particular,
older patients are perceived as being less able to tolerate
chemotherapy well [38]. Additionally, doctors perceive
that a short life expectancy may limit the benefits of
chemotherapy, although it has also been shown that
chemotherapy does increase the time to recurrence and
overall survival in older patients [11]. Some research has
provided evidence that doctors may be less likely to offer
adjuvant treatments to older patients [39], and in terms
of patient preferences, it has been reported that older
patients more frequently decline adjuvant therapy, espe-
cially if they lack social support [6, 40]. Yellen et al.
found that older patients were not less likely to accept
chemotherapy than younger patients but that they were
less willing to accept a greater level of toxicity in ex-
change for longer survival [41].
In our health system, the odds of use of both adjuvant
chemotherapy for colon cancer and preoperative radio-
therapy for rectal cancer decrease dramatically with age.
This conclusion can be partially but not completely ex-
plained by a higher frequency and severity of comorbidity
among older patients. Nevertheless, curative resection,
tumour characteristics and social factors such as
deprivation, level of education and living arrangements
did not help to explain the observed differences in
treatment by age. Indeed, after adjusting for all these
factors, significant differences between age groups
remained. Further research is required to assess the im-
pact of the functional, cognitive and motor status of pa-
tients as well as doctors’ knowledge and attitudes and
the preferences of patients and their relatives. Some
studies have reported the usefulness of including geriat-
ric assessment tools for daily clinical practice, although
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their application for identifying patients who are good
candidates for adjuvant treatments is not clear, and fur-
ther research is needed to assess the role of these tools
in oncological treatment [3, 42].
Conclusions
The probability of older patients with colorectal cancer
receiving adjuvant chemotherapy and preoperative
radiotherapy is lower than that of younger patients and
many of them are not receiving the treatments recom-
mended by clinical practice guidelines. Differences in
comorbidity, tumour characteristics, curative resection,
and socioeconomic factors do not explain this lower
probability of treatment. Research is needed to identify
the role of physical and cognitive functional status, doc-
tors’ attitudes, and preferences of patients and their rel-
atives, in the use of adjuvant therapies.
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